PYPD Polypid

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025.

The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on Sunday, September 7, 2025, from 5:25 PM - 5:45 PM local time as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."

About PolyPid

PolyPid Ltd. (Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,  PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit  and follow us on  and .

Company Contact:

PolyPid Ltd. 

Ori Warshavsky

908-858-5995

Investor & IR Contact:

Arx | Capital Markets

North American Equities Desk



EN
02/09/2025

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference an...

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025. Additionally, management will be participating in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. Ly...

September 17, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspecti...

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3 Trial PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of a routine Good Manufacturing Practice (GMP) inspection by t...

September 16, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Glo...

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City. PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, w...

September 3, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Present at the 14th Meeting of the Israel Controlled Releas...

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025. The presentation, titled "Novel Local Prolonged Drug Deliver...

September 2, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Fina...

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes Market Successful Warrant Exercise Significantly Strengthened Balance Sheet with Cash Runway into 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PY...

August 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch